Truist Financial Has Lowered Expectations for Medpace (NASDAQ:MEDP) Stock Price

Medpace (NASDAQ:MEDP) had its price objective reduced by equities researchers at Truist Financial from $555.00 to $539.00 in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s price objective indicates a potential upside of 29.55% from the stock’s current price.

Several other equities analysts have also weighed in on the company. BMO Capital Markets began coverage on Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective for the company. Mizuho set a $660.00 price objective on shares of Medpace in a research note on Friday, January 9th. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a research note on Tuesday. TD Cowen reissued a “sell” rating on shares of Medpace in a report on Friday, October 24th. Finally, Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Three equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $477.36.

Medpace Trading Down 1.9%

Shares of MEDP opened at $416.04 on Wednesday. The stock has a 50 day moving average of $569.92 and a 200 day moving average of $537.90. The company has a market capitalization of $11.81 billion, a price-to-earnings ratio of 27.19, a PEG ratio of 1.37 and a beta of 1.42. Medpace has a 12 month low of $250.05 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts predict that Medpace will post 12.29 earnings per share for the current year.

Insider Activity

In related news, CFO Kevin M. Brady sold 3,000 shares of the stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at $3,542,100. This represents a 33.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO August J. Troendle sold 668 shares of Medpace stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the transaction, the chief executive officer directly owned 646,184 shares in the company, valued at $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 270,533 shares of company stock valued at $163,122,826. Corporate insiders own 20.30% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several institutional investors have recently added to or reduced their stakes in the company. Clarkston Capital Partners LLC bought a new stake in Medpace during the second quarter valued at approximately $40,569,000. Brighton Jones LLC grew its stake in shares of Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after acquiring an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Medpace by 150.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after purchasing an additional 9,117 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of Medpace by 12.0% in the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after purchasing an additional 62,503 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Medpace by 14.8% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 55,861 shares of the company’s stock valued at $28,721,000 after buying an additional 7,194 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.